Related Experiment Video
Updated: Mar 21, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
[Recent advances in pharmacological intervention for prediabetes]
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|May 13, 2016
Summary
Prediabetes, a precursor to type 2 diabetes, can be managed through lifestyle changes and medications. This review explores pharmacological interventions and animal models for impaired glucose tolerance (IGT), offering insights into diabetes prevention strategies.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Prediabetes signifies an intermediate metabolic state between normal glucose regulation and type 2 diabetes mellitus.
- Impaired glucose tolerance (IGT) is a key indicator of elevated prediabetes risk.
- Effective interventions for IGT can delay or prevent progression to type 2 diabetes, highlighting its critical role in diabetes prevention.
Purpose of the Study:
- To review current clinical and preclinical research on pharmacological interventions for prediabetes.
- To examine the development and application of animal models for studying impaired glucose tolerance (IGT).
- To discuss the future potential of pharmaceutical agents, including traditional Chinese medicine, for diabetes prevention.
Main Methods:
- Comprehensive literature search of clinical and preclinical studies on prediabetes pharmacological interventions.
- Analysis of research on the development and utilization of animal models exhibiting IGT.
- Review of emerging techniques and traditional Chinese medicine applications in diabetes prevention.
Main Results:
- Pharmacological interventions for prediabetes are an emerging area of research.
- Animal models are crucial for understanding IGT and testing potential therapeutic strategies.
- Traditional Chinese medicine shows promise as a complementary approach to diabetes prevention.
Conclusions:
- Impaired glucose tolerance (IGT) presents a critical window for intervention to prevent type 2 diabetes.
- Further research into pharmacological treatments and novel therapeutic approaches, including traditional Chinese medicine, is warranted for prediabetes management.
- Development of effective drugs for diabetes prevention is a key goal, with IGT as a primary target.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
909
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
909
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
982
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
982
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
839
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
839
01:06Oral Hypoglycemic Agents: Glinides
921
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
921